SLC2A1 and liver dysplastic nodule: Glucose or other sugar base ligands may be employed to target GLUT1 on glomerular mesangial cells for effective and targeted drug delivery in DN, resulting in improved bioavailability of several drugs (68, 98, 109, 139).